The China Health Ecology Organization (CPEO), themed "Dual Collaboration for Industry Reshaping – Initiating a New Era of Individual Health Responsibility," was recently held in Boao, Hainan. During the conference, Li Kun, the President of Zhendong Health Industry Group (referred to as Zhendong Health), was featured on the program "China Medicine Influence – High-Quality Development of Pharmaceutical Enterprises." He engaged in a conversation with Xu Li who is a specially appointed expert from the Institute of Pharmaceutical Brands at People's Health Research Institute and the founder of Focus Brand Consulting, and Wei Xin who is the host of People's Health. According to Li Kun, the high-quality development of traditional Chinese medicine (TCM) enterprises is primarily achieved through two avenues: one is enhancing innovation in new products and medicines to continuously meet public health demands; another is accelerating internationalization efforts to introduce TCM products globally.

It is understood that the integration of internationalization and localization is a crucial "gene" in Zhendong Group's TCM research and development innovation. Since 2008, Zhendong Health has launched the international layout of research and development, and has set up research and development laboratories in the United States, Australia and other places to carry out in-depth cooperation with foreign scientific research institutions and experts. "Zhendong Group's origins lie in traditional Chinese medicine. In the process of internationalization, we believe that the overseas expansion of TCM should not be solely focused on sales or branding, but should prioritize research prelude," according to Li Kun. He believes that "to involve foreign experts deeply in research and gain genuine recognition for TCM-related products, we must earn the approval of experts first. Only with their recognition can we gain acceptance from overseas consumers. This is the core of Zhendong Health's overseas research layout."

At present, TCM is rapidly gaining traction on the global stage. In this process, In this process, how to continuously enhance the international competitiveness of Chinese medicine and promote Chinese medicine to go out needs the joint efforts of the industry. Li Kun believes that in the internationalization of TCM, providing high-quality products is a primary step. It is not only about meeting the "bottom line" of overseas market standards, but also pursuing a "higher standard" of product quality. Additionally, it requires the creation of high-quality international teams that can adapt to foreign cultures, consumer demands, and distribution requirements. Based on this foundation, advanced management concepts should be implemented to support the collaborative efforts between overseas and domestic teams.

Li Kun introduced that Zhendong Health currently focuses primarily on four major areas: TCM oncology, dermatology, urology, and digestion. Leveraging its accumulated product advantages, Zhendong Health will continue its long-term research investment in these four domains. While expanding in domestic and international markets, the company will also concurrently advance complementary work in domestic and international research. Moreover, as public attention towards scalp health rises, new demands in scalp health have emerged. In response, Zhendong Health concentrates on hair growth products, striving to provide consumers with high-quality solutions for hair loss through innovative research and development in aspects such as gender-specific formulations, sensory experience, and adverse reactions.